The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 06, 2022

Filed:

Nov. 18, 2019
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

Andre E. Nel, Sherman Oaks, CA (US);

Huan Meng, Los Angeles, CA (US);

Kuo-Ching Mei, Los Angeles, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 47/69 (2017.01); A61K 47/55 (2017.01); A61K 47/54 (2017.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 47/6929 (2017.08); A61K 47/542 (2017.08); A61K 47/544 (2017.08); A61K 47/551 (2017.08); A61K 47/554 (2017.08); A61K 47/6905 (2017.08); A61K 47/6923 (2017.08); B82Y 5/00 (2013.01);
Abstract

In certain embodiments a platform technology for the facilitating immune therapy in the treatment of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor-prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB)-coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.


Find Patent Forward Citations

Loading…